Clinical trials: Histological Response
Kidney Cancer, Melanoma (Skin)
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00006022
- Testing
- aldesleukin, bryostatin 1
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Virginia Commonwealth University
HEAD AND NECK CANCER, CARCINOMA OROPHARYNX
Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.
This study aims to study the impact image guided radiotherapy with Cone beam CT will have on the outcomes(toxicities and response) of head and neck cancer when compared to 3D conformal radiotherapy without CBCT based setup error…
- Conditions
- HEAD AND NECK CANCER, CARCINOMA OROPHARYNX, CARCINOMA PYRIFORM SINUS, CARCINOMA LARYNX
- Trial name
- NCT01124409
- Testing
- EPID Verification, CBCT verification
- Where
- India
- Volunteers
- 41 people
- Sponsor
- All India Institute of Medical Sciences
Stage IIA Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
This randomized pilot clinical trial studies pazopanib hydrochloride followed by chemotherapy and surgery in treating patients with soft tissue sarcoma.
- Conditions
- Stage IIA Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT01446809
- Testing
- Doxorubicin Hydrochloride, External Beam Radiation Therapy, Ifosfamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Washington
Acute Lymphoblastic Leukemia, Adult B-Cell
Impact of Cross-training on Induction Treatment Response in Acute Lymphoblastic Leukemia Adults
Despite advances in the treatment of acute lymphoblastic leukemia, the prognosis in adults is still poor, largely due to the resistance of treatment at diagnosis or early relapse.
- Trial name
- NCT05059847
- Testing
- Training
- Where
- Mexico
- Volunteers
- 114 people
- Sponsor
- Hospital General de Mexico
Leukemia, Leukemia, Myeloid
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/ or Dasatinib, Nilotinib)…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Philadelphia Chromosome
- Trial name
- NCT01602952
- Testing
- Radotinib
- Where
- 12 sites in India, South Korea and 1 more
- Volunteers
- 85 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Relapsed/Refractory Multiple Myeloma (RRMM)
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who…
- Trial name
- POPLIN (NCT07609940)
- Testing
- Linvoseltamab, Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
There is no study hypothesis. The purpose of this study is to see if the Pneumococcal conjugate vaccine (PCV13), when administered before and early after an autologous peripheral stem cell transplant will induce an immune…
- Trial name
- PCV13 (NCT01852591)
- Testing
- PCV 13
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
This phase II trial studies how well dabrafenib, trametinib, and spartalizumab works in treating patients with BRAF V600E or V600K mutation positive stage IIIB/C/D melanoma, who do not achieve a pathologic complete response after…
- Conditions
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Trial name
- NCT04310397
- Testing
- Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Follicular Lymphoma
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program…
- Trial name
- MosuOSSHSR (NCT07278921)
- Testing
- Mosunetuzumab
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Andrés José Maria Ferreri
Nasal Type Extranodal NK/T-Cell Lymphoma
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma
This open-label, single arm study will evaluate the efficacy and safety of anti-PD-1 antibody in combination with pegaspargase in treatment of newly diagnosed advanced stage NK/T-cell lymphoma.
- Trial name
- NCT04096690
- Testing
- Pegaspargase, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Ruijin Hospital
Hepatocellular Carcinoma
Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma
Positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG-PET) evaluates cancer cell glycolysis(Warburg effect) as a surrogate for tumor response.The hypothesis of this study is that early changes in FDG-PET signal can…
- Trial name
- NCT01157013
- Testing
- Positron emission tomography with fludeoxyglucose F 18
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital Miguel Servet
Multiple Myeloma
Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation
Hematopoietic reconstitution defined by a neutrophils number > 500/mm3 at day 7 after injection of ex vivo amplified graft and by a platelets number > 20000/mm3, at day 15 after the injection of ex vivo amplified graft, without…
- Trial name
- Expansion (NCT00461955)
- Testing
- autologous peripheral blood stem cell transplantation, ex vivo amplified
- Where
- France
- Volunteers
- 13 people
- Sponsor
- University Hospital, Bordeaux
Glioblastoma Multiforme, Anaplastic Astrocytoma
Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.
Subjects with newly diagnosed brain tumors who undergo surgical resection and whose pathology in the operating room shows a high grade glioma will be eligible.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- Gliadel-MRS (NCT00645385)
- Testing
- MRS Spectroscopy
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Chronic Myeloid Leukaemia
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
The purpose of this study is to investigate whether some patients with excellent responses to chronic myeloid leukaemia (CML) treatment are being overtreated, and can remain well on either a lower dose of treatment or without…
- Trial name
- DESTINY (NCT01804985)
- Testing
- Imatinib, nilotinib, dasatinib
- Where
- United Kingdom
- Volunteers
- 174 people
- Sponsor
- University of Liverpool
Malignant Glioma
Study of Capecitabine to Treat Recurrent High Grade Gliomas
The purpose of this study is to determine if capecitabine is effective in the treatment of high grade gliomas that have returned after completing treatment.
- Trial name
- NCT00717197
- Testing
- Capecitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Glioblastoma, Glioma, Malignant
GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
The purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma (GBM), and to determine if plasma circulating tumor DNA (ctDNA) or cell free DNA (cfDNA) is associated with disease…
- Trial name
- NCT05695976
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Duke University
Bone Sarcoma, Osteosarcoma
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse.
- Trial name
- REGOMAIN (NCT04698785)
- Testing
- Treatment by regorafenib and best supportive care
- Where
- 16 sites in France
- Volunteers
- 36 people
- Sponsor
- Centre Leon Berard
Metastatic Renal Cell Carcinoma
A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer
The primary objective of this study is to answer the question "Is it possible to inject the Combig-DC vaccine in a renal tumour without getting unacceptable side effects"? Patients newly diagnosed with metastatic renal cell…
- Trial name
- NCT01525017
- Testing
- Combig-DC (allogeneic dendritic cells) Cancer Vaccine
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Mendus
Gingival Pigmentation
The Adjunctive Role of Vitamin C on Pigment Recurrence (Randomized Clinical and Histological Trial)
The goal of this clinical trial is to determine the role of vitamin C on recurrence of gingival pigment after patients who are healthy and esthetically concerned with it received surgical removal of this pigment.
- Trial name
- NCT06312605
- Testing
- Injectable applied vitamin C, Topical applied Vitamin C, Surgical depigmentation only
- Where
- Egypt
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Brain Neoplasms
Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy
Recurrent brain tumours are extremely aggressive and despite optimal treatment, median survival is less than two years. One of the standard treatment options in this situation is radiation therapy.
- Trial name
- SMC 0712-13 (NCT02149459)
- Testing
- Partial brain re-irradiation., Metformin, low carbohydrate diet
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Sheba Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.